RecruitingPhase 2NCT06807580

Progesterone in Gender Affirming Hormone Therapy Study

Effects of Oral Progesterone in Transgender Women on Breast Development, Sleep Quality, Psychological Distress, and Cardiovascular Risk


Sponsor

Emory University

Enrollment

40 participants

Start Date

May 12, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to study the effects of Oral Progesterone in Transgender Women. The primary goal is to study the effect of progesterone on psychological distress and secondarily on sleep quality, breast size, quality of life and gender congruence and cardiovascular risk.


Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 60 Years

Inclusion Criteria1

  • \- Participants will be transgender women, who have been on gender-affirming hormone therapy for at least 6 months before the start of the study.

Exclusion Criteria22

  • Peanut allergy
  • Liver disease (liver enzyme elevations and/or evidence of acute or chronic hepatitis). In our lab, the upper limit of normal for aspartate aminotransferase (AST) is 39, and the upper limit of normal for alanine aminotransferase (ALT) is 52.
  • Stage 4/5 chronic kidney disease
  • Congestive heart failure
  • Medical disease or medication use associated with gynecomastia (i.e tumor, hyperthyroidism, chronic kidney disease, cirrhosis, ACE inhibitors, statins, haloperidol, tricyclic antidepressants, atypical antipsychotics)
  • Pre-existing cardiovascular disease
  • Prior or current history of thromboembolism, known clotting disorders, current or recent anti-thrombotic therapy for venous thromboembolism.
  • History of breast cancer
  • Prior progesterone use
  • Uncontrolled depression and/or suicidal ideation
  • Current hypothyroidism (even if controlled with treatment) Progesterone in Gender Affirming Hormone Therapy 9 Version #4, 10/30/24
  • Cannabis use of greater than 1 use/week in the past 3 months
  • Previously identified BRCA 1 or 2 gene mutation or other familial breast cancer.
  • Abnormal mammogram (if indicated - for patients above the age of 50 and on estrogen for 5 or more years OR positive family history of breast cancer) with results of BIRADS 3 or higher. Subjects with a BIRADS 0 mammogram must have undergone additional imaging demonstrating BIRADS 1 or 2 prior to enrollment.
  • Have had or are planning to undergo breast enhancement or gender affirming top surgery in the next 6 months
  • Uncontrolled hypertension, defined as systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mmHg.
  • Triglycerides ≥ 500 mg/dL.
  • In our lab, the upper limit of normal for aspartate aminotransferase (AST) is 39, and the upper limit of normal for alanine aminotransferase (ALT) is 52.
  • Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2.
  • Estradiol levels outside the stable range (100-300 pg/mL)
  • Heavy smoking, defined as 25+ cigarettes per day
  • Non-English speaking or those with limited English proficiency

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPlacebo

The placebo will be nearly identical in size, color, and shape to micronized progesterone

DRUGProgesterone

Oral micronized progesterone 200 mg


Locations(1)

Emory Transgender Clinic

Atlanta, Georgia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06807580


Related Trials